- Home
- PRT vs TPST Comparison
PRT vs TPST Comparison
Compare PRT & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- TPST
- Stock Information
- Founded
- PRT 2017
- TPST 2011
- Country
- PRT United States
- TPST United States
- Employees
- PRT N/A
- TPST N/A
- Industry
- PRT Oil & Gas Production
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- PRT Energy
- TPST Health Care
- Exchange
- PRT Nasdaq
- TPST Nasdaq
- Market Cap
- PRT 47.7M
- TPST 45.5M
- IPO Year
- PRT N/A
- TPST N/A
- Fundamental
- Price
- PRT $3.79
- TPST $10.14
- Analyst Decision
- PRT
- TPST Hold
- Analyst Count
- PRT 0
- TPST 3
- Target Price
- PRT N/A
- TPST $30.00
- AVG Volume (30 Days)
- PRT 35.0K
- TPST 60.6K
- Earning Date
- PRT 11-12-2025
- TPST 11-11-2025
- Dividend Yield
- PRT 11.43%
- TPST N/A
- EPS Growth
- PRT 1.16
- TPST N/A
- EPS
- PRT 0.44
- TPST N/A
- Revenue
- PRT $6,314,770.00
- TPST N/A
- Revenue This Year
- PRT N/A
- TPST N/A
- Revenue Next Year
- PRT N/A
- TPST N/A
- P/E Ratio
- PRT $8.65
- TPST N/A
- Revenue Growth
- PRT 1.82
- TPST N/A
- 52 Week Low
- PRT $3.26
- TPST $5.35
- 52 Week High
- PRT $4.63
- TPST $20.67
- Technical
- Relative Strength Index (RSI)
- PRT 33.58
- TPST 53.41
- Support Level
- PRT $3.84
- TPST $9.90
- Resistance Level
- PRT $3.89
- TPST $11.02
- Average True Range (ATR)
- PRT 0.08
- TPST 0.63
- MACD
- PRT -0.02
- TPST -0.15
- Stochastic Oscillator
- PRT 5.29
- TPST 33.51
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.